Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 2Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Genital Neoplasms, Female 1Colorectal Neoplasms 1Cholangiocarcinoma 1Cardiotoxicity 1Carcinoma 1Atrial Fibrillation 1Appendiceal Neoplasms 1

Interventions

tremelimumab 1pembrolizumab 1nilotinib 1durvalumab 1Trastuzumab 1Psychiatric Rehabilitation 1Paclitaxel 1Oxaliplatin 1Methods 1Leucovorin 1Laparoscopy 1Gemcitabine 1Fluorouracil 1Electrocardiography 1Early Intervention, Educational 1EC regimen 1Cisplatin 1Carboplatin 1CP protocol 1Behavior Therapy 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peritoneal Neoplasms × Electrocardiography × Breast × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡